Tiziana Life Sciences Ltd (TLSA) - Net Assets

Latest as of March 2026: $52.00K USD

Based on the latest financial reports, Tiziana Life Sciences Ltd (TLSA) has net assets worth $52.00K USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.49 Million) and total liabilities ($11.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tiziana Life Sciences Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $52.00K
% of Total Assets 0.45%
Annual Growth Rate -13.03%
5-Year Change -99.87%
10-Year Change -98.43%
Growth Volatility 246.07

Tiziana Life Sciences Ltd - Net Assets Trend (1998–2025)

This chart illustrates how Tiziana Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. See Tiziana Life Sciences Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Tiziana Life Sciences Ltd (1998–2025)

The table below shows the annual net assets of Tiziana Life Sciences Ltd from 1998 to 2025. For live valuation and market cap data, see TLSA market cap.

Year Net Assets Change
2025-12-31 $52.00K -98.68%
2024-12-31 $3.94 Million -28.90%
2023-12-31 $5.54 Million -71.71%
2022-12-31 $19.57 Million -52.59%
2021-12-31 $41.28 Million -33.83%
2020-12-31 $62.39 Million +1592.49%
2019-12-31 $-4.18 Million -1121.97%
2018-12-31 $409.01K +124.30%
2017-12-31 $-1.68 Million -150.78%
2016-12-31 $3.31 Million -61.03%
2015-12-31 $8.50 Million +378.56%
2014-12-31 $1.78 Million +1317.12%
2013-12-31 $-146.00K -265.00%
2012-12-31 $-40.00K -107.62%
2011-12-31 $525.00K -13.08%
2010-12-31 $604.00K -50.21%
2009-12-31 $1.21 Million -9.48%
2008-12-31 $1.34 Million -45.08%
2007-12-31 $2.44 Million +0.49%
2006-12-31 $2.43 Million -14.05%
2005-12-31 $2.83 Million -20.27%
2004-12-31 $3.54 Million +17.05%
2003-12-31 $3.03 Million +37.28%
2002-12-31 $2.21 Million -25.56%
2001-12-31 $2.96 Million -26.08%
2000-12-31 $4.01 Million +101.97%
1999-12-31 $1.98 Million -11.94%
1998-12-31 $2.25 Million --

Equity Component Analysis

This analysis shows how different components contribute to Tiziana Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 4414000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $121.00K 232.69%
Other Comprehensive Income $9.68 Million 18615.38%
Other Components $34.66 Million 66659.62%
Total Equity $52.00K 100.00%

Tiziana Life Sciences Ltd Competitors by Market Cap

The table below lists competitors of Tiziana Life Sciences Ltd ranked by their market capitalization.

Company Market Cap
Song Hong Garment JSC
VN:MSH
 $147.71 Million
Orthocell Ltd
AU:OCC
 $147.82 Million
Areeya Property Public Company Limited
BK:A
 $147.84 Million
Cheil Electric Wiring Devices Co. Ltd.
KQ:199820
 $147.87 Million
Decisive Dividend Corp
V:DE
 $147.52 Million
Combined Motor Holdings Limited
JSE:CMH
 $147.51 Million
Curiositystream Inc.
NASDAQ:CURI
 $147.50 Million
Curo Holdings Co. Ltd
KQ:051780
 $147.46 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tiziana Life Sciences Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 3,936,000 to 52,000, a change of -3,884,000 (-98.7%).
  • Net loss of 18,431,000 reduced equity.
  • Other comprehensive income decreased equity by 107,310,000.
  • Other factors increased equity by 121,857,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-18.43 Million -35444.23%
Other Comprehensive Income $-107.31 Million -206365.38%
Other Changes $121.86 Million +234340.38%
Total Change $- -98.68%

Book Value vs Market Value Analysis

This analysis compares Tiziana Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1319.31x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.00x to 1319.31x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1998-12-31 $2627.04 $1.16 x
1999-12-31 $2391.57 $1.16 x
2000-12-31 $4892.55 $1.16 x
2001-12-31 $2829.04 $1.16 x
2002-12-31 $957.86 $1.16 x
2003-12-31 $647.07 $1.16 x
2004-12-31 $640.34 $1.16 x
2005-12-31 $346.50 $1.16 x
2006-12-31 $191.35 $1.16 x
2007-12-31 $138.10 $1.16 x
2008-12-31 $40.96 $1.16 x
2009-12-31 $11.71 $1.16 x
2010-12-31 $1.72 $1.16 x
2011-12-31 $0.80 $1.16 x
2012-12-31 $-0.04 $1.16 x
2013-12-31 $-0.01 $1.16 x
2014-12-31 $0.31 $1.16 x
2015-12-31 $0.18 $1.16 x
2016-12-31 $0.06 $1.16 x
2017-12-31 $-0.03 $1.16 x
2018-12-31 $0.01 $1.16 x
2019-12-31 $-0.06 $1.16 x
2020-12-31 $0.94 $1.16 x
2021-12-31 $0.84 $1.16 x
2022-12-31 $0.39 $1.16 x
2023-12-31 $0.11 $1.16 x
2024-12-31 $0.07 $1.16 x
2025-12-31 $0.00 $1.16 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tiziana Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -35444.23%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 221.06x
  • Recent ROE (-35444.23%) is below the historical average (-1435.10%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1998 -12.07% 0.00% 0.00x 1.19x $-497.40K
1999 -27.91% 0.00% 0.00x 1.18x $-752.50K
2000 -56.60% 0.00% 0.00x 1.12x $-2.67 Million
2001 -78.49% 0.00% 0.00x 1.12x $-2.62 Million
2002 -104.58% 0.00% 0.00x 1.16x $-2.53 Million
2003 -64.82% 0.00% 0.00x 1.09x $-2.26 Million
2004 -39.18% -1402.02% 0.02x 1.17x $-1.74 Million
2005 -75.79% -1845.69% 0.03x 1.22x $-2.42 Million
2006 -89.62% -537.28% 0.13x 1.30x $-2.42 Million
2007 -99.06% -3776.56% 0.02x 1.19x $-2.66 Million
2008 -106.64% -1553.26% 0.05x 1.48x $-1.56 Million
2009 -60.18% -1303.57% 0.03x 1.43x $-851.30K
2010 -774.51% 0.00% 0.00x 1.69x $-4.74 Million
2011 -230.08% 0.00% -0.20x 1.19x $-1.26 Million
2012 0.00% 0.00% 0.00x 0.00x $-844.00K
2013 0.00% -9333.33% 0.02x 0.00x $-265.40K
2014 -197.52% 0.00% 0.00x 1.38x $-3.69 Million
2015 -150.38% 0.00% 0.00x 1.09x $-13.64 Million
2016 -217.50% 0.00% 0.00x 1.52x $-7.54 Million
2017 0.00% 0.00% 0.00x 0.00x $-6.60 Million
2018 -1540.08% 0.00% 0.00x 13.33x $-6.34 Million
2019 0.00% 0.00% 0.00x 0.00x $-6.89 Million
2020 -57.17% 0.00% 0.00x 1.55x $-30.70 Million
2021 -56.73% 0.00% 0.00x 1.18x $-27.55 Million
2022 -78.67% 0.00% 0.00x 1.35x $-17.35 Million
2023 -319.56% 0.00% 0.00x 2.20x $-18.24 Million
2024 -301.40% 0.00% 0.00x 2.87x $-12.26 Million
2025 -35444.23% 0.00% 0.00x 221.06x $-18.44 Million

Industry Comparison

This section compares Tiziana Life Sciences Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $27,896,581
  • Average return on equity (ROE) among peers: -64.77%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tiziana Life Sciences Ltd (TLSA) $52.00K -12.07% 220.06x $147.62 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-54.64 Million 0.00% 0.00x $85.57 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $1.61 Billion
Abeona Therapeutics Inc (ABEO) $4.06 Million -282.32% 0.21x $328.21 Million
Acumen Pharmaceuticals Inc (ABOS) $70.43 Million -172.28% 0.74x $155.29 Million
Abpro Holdings, Inc. (ABP) $-75.73 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $189.45 Million -60.80% 0.14x $1.01 Billion
Arbutus Biopharma Corp (ABUS) $35.44 Million -26.32% 0.18x $831.63 Million
ABVC Biopharma Inc (ABVC) $-1.46 Million 0.00% 0.00x $35.10 Million
Abivax SA American Depositary Shares (ABVX) $34.02 Million -17.32% 0.13x $7.90 Billion
ACADIA Pharmaceuticals Inc (ACAD) $67.16 Million -67.08% 0.33x $3.66 Billion

About Tiziana Life Sciences Ltd

NASDAQ:TLSA USA Biotechnology
Market Cap
$147.62 Million
Market Cap Rank
#17806 Global
#4134 in USA
Share Price
$1.16
Change (1 day)
+7.41%
52-Week Range
$1.08 - $2.50
All Time High
$6.93
Categories
Companies in USA Biotechnology
About

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more